From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis

Area of Science:

• Endocrinology
• Vascular Biology
• Pharmacology

Background:

• The prolactin/vasoinhibin axis is an endocrine system regulating blood vessel growth, hormone secretion, immunity, and behavior.
• Vasoinhibins are generated by proteolytic cleavage of prolactin (PRL) and exhibit pleiotropic effects.
• Dysregulation of this axis is implicated in various pathologies.

Purpose of the Study:

• To explore therapeutic interventions targeting the prolactin/vasoinhibin axis.
• To evaluate the efficacy of levosulpiride in diabetic retinopathy and bromocriptine in peripartum cardiomyopathy.

Main Methods:

• Clinical trial investigating levosulpiride (dopamine D2-receptor antagonist) for diabetic macular edema.
• Clinical trial investigating bromocriptine (dopamine D2-receptor agonist) for peripartum cardiomyopathy.
• Assessment of vasoinhibin levels as a therapeutic target.

Main Results:

• Bromocriptine treatment in peripartum cardiomyopathy was associated with significant left ventricular recovery and reduced morbidity/mortality.
• Levosulpiride aims to increase vasoinhibins to counteract diabetes-induced retinal damage.
• Interventions carry potential risks affecting blood pressure, coagulation, and mental state.

Conclusions:

• The prolactin/vasoinhibin axis represents a viable target for therapeutic interventions.
• Bromocriptine shows significant clinical benefit in peripartum cardiomyopathy.
• Further research is needed to fully understand and mitigate risks associated with targeting this axis.